Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
EyePoint Pharmaceuticals, Inc.
Study ID
NCT06099184
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept

Key Dates

Start date
Jan 15, 2024
Status verified
Sep 2024
Primary completion
Oct 24, 2024
Completion
Oct 24, 2024

Study Design

Enrollment
27 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: EYP-1901 1343 µg
    EYP-1901 1343 µg, single dose
  • Experimental: EYP-1901 2686 µg
    EYP-1901 2686 µg, single dose
  • Active Comparator: Aflibercept
    Aflibercept 2 mg/0.05mL solution, single dose

Primary Outcome Measure

Time to first supplemental aflibercept injection following EYP-1901 dose at Baseline vs Aflibercept [ Time Frame: Week 24 ]

Locations (6)

FacilityCityStateZIPSite coordinators
EyePoint Investigative SitePhoenixArizona85020-
EyePoint Investigative SiteLemontIllinois60439-
EyePoint Investigative SiteHagerstownMaryland21740-
EyePoint Investigative SiteRenoNevada89502-
EyePoint Investigative SiteEriePennsylvania16507-
EyePoint Investigative SiteLynchburgVirginia24502-

Find similar trials in Phoenix, AZ

By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
EyePoint Investigative Site· Phoenix, AZEyePoint Investigative Site· Lemont, ILEyePoint Investigative Site· Hagerstown, MDEyePoint Investigative Site· Reno, NVEyePoint Investigative Site· Erie, PAEyePoint Investigative Site· Lynchburg, VA

Related Studies